Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre-funded warrants on February 26, 2026.The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre-funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of their option to purchase additional shares of stock in the offering. All shares and pre-funded warrants were sold by Zura.Gross proceeds from the offering were approximately $144 million, before deducting underwriting discounts and commissions and other offering exp
Show less
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsBusiness Wire
- Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsBusiness Wire
- Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of DirectorsBusiness Wire
- Zura Bio (NASDAQ:ZURA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.MarketBeat
- Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech SummitBusiness Wire
ZURA
Earnings
- 11/13/25 - Miss
ZURA
Sec Filings
- 2/26/26 - Form 8-K/A
- 2/26/26 - Form 8-K
- 2/25/26 - Form 424B5
- ZURA's page on the SEC website